Cue Biopharma, Inc.

Analysis for Ticker: CUE

Cue Biopharma Inc uses its proprietary platform to create injectable biologics that train a patient's own immune cells to selectively target and fight cancer and autoimmune diseases. The company is operating behind a mechanical illusion after executing a massive 1-for-30 reverse stock split on 23/04/2026, a move designed solely to hide its status as a penny stock and artificially inflate its share price to meet exchange requirements. Despite a 30$ million capital raise in 05/2026 and an artificially propped market cap of 99$ million, the internal math is a disaster because management has officially issued a going concern warning, admitting the entity does not have enough capital on hand to survive beyond the first quarter of 2027. To a child, this looks like a lemonade stand that spends more on its fancy signs and its workers' lunches than it makes from selling juice, and it only has enough coins left in its jar to stay open for a few more months before it has to close for good.